We have changed our domainWe have changed servers and operate Career|edu under a different domain. Our services will remain unchanged and we will continue to post the best career openings for the academic world at our new domain.
Go back to the Job List
Immunogenicity of Vectors in Gene TherapyPosted by: Postdoc positions by NIH
Posted date: 2020-Feb-07
A research opportunity is available in the Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies (OTAT), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
Adeno-associated virus (AAV) is a small viral vector commonly used for gene delivery. AAV based gene therapies are beginning to show clinical successes. However, due to the viral origin of AAV, there is a growing body of evidence demonstrating interactions of AAV vectors with the innate and adaptive immune system which hinders their successful translation from the bench to the bedside.
Our lab’s goal is to develop technologies to help evaluate and mitigate the adaptive immunogenicity of AAV vectors in gene therapy. Under the guidance of a mentor, the selected participant will help to rationally design next generation AAV vectors with lower immunogenicity and test the efficacy of these designs in mice models. The participant will perform research in a highly translational and collaborative environment and learn techniques including AAV production and quantification, cloning, mutagenesis, and humoral and cellular immunological assays.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for five months, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.Qualifications:
The qualified candidate should be currently pursuing or have received a doctoral degree in Chemistry, Engineering, Life Health and Medical Sciences, Nanotechnology, or a related field. Degree must have been received within five years of the appointment start date. Preferred skills are:
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years. FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency.To Apply:
A complete application consists of:
All documents must be in English or include an official English translation.
If you have questions, send an email to ORISE.FDA.CBERorau.org. Please include the reference code for this opportunity (FDA-CBER-2020-0010) in your email.